Search

Hanne Gron

from Larkspur, CA
Age ~61
Get Report
Also known as:
Hanne Etal Gron
Phone and address:
81 Elm Ave, Larkspur, CA 94939
(415) 823-4465
Related to:
Annette N Berry, 59Darren D Harris, 47Catherine M Harris, 51Ingrid J Gron, 53Thomas JuulLouise C Juul, 78Jakob Gron, 53Paul William Juul, 79
Connected to:
Alan R Gron, 46Albert J Gron, 61Rene A Gron, 64Audra D Grona, 50Michael J Grona, 39Terri A Grona, 57William Grona, 53Elizabeth O Gronager, 69Chad N Gronan, 41Carol S Gronau, 88

Hanne Gron Phones & Addresses

  • 81 Elm Ave, Larkspur, CA 94939 (415) 823-4465
  • 5 Winthrop Ct, Durham, NC 27707
  • 5 Winthrop Ct #H7, Durham, NC 27707
  • 914 Monmouth Ave #1, Durham, NC 27701
  • 6123 Farrington Rd #7, Chapel Hill, NC 27517
  • 81 Elm Ave, Larkspur, CA 94939

Business Records

Name / Title
Company / Classification
Phones & Addresses
Hanne Gron
Engineering-Research & Development Manager
Affinergy, Inc
Commercial Physical Research · Research & Development in Biotechnology
617 Davis Dr, Durham, NC 27713
PO Box 14650, Durham, NC 27709
617 Davis Dr STE 100, Morrisville, NC 27560
(919) 433-2200, (919) 474-9407

Publications

Us Patents

Anti-Cd19 Antibodies And Uses In B Cell Disorders

View page
US Patent:
8444973, May 21, 2013
Filed:
Sep 17, 2010
Appl. No.:
12/885341
Inventors:
Thomas F. Tedder - Durham NC, US
Yasuhito Hamaguchi - Kanazawa, JP
Hanne Gron - Durham NC, US
Norihito Yazawa - Tokyo, JP
Assignee:
Duke University - Durham NC
International Classification:
A61K 39/395
US Classification:
4241301
Abstract:
The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.

Compositions And Methods For Delivery Of Glycopeptide Antibiotics To Medical Device Surfaces

View page
US Patent:
8637455, Jan 28, 2014
Filed:
Oct 17, 2008
Appl. No.:
12/739353
Inventors:
Martyn K. Darby - Chapel Hill NC, US
Isaac G. Sanford - Durham NC, US
R. Edward Benson - Durham NC, US
Hanne Gron - Durham NC, US
Paul T. Hamilton - Cary NC, US
Shrikumar A. Nair - Cary NC, US
Doug Buechter - Chester Springs PA, US
Elliott Gruskin - Malvern PA, US
Assignee:
Affinergy, LLC - RTP NC
DePuy Synthes Products, LLC - Raynham MA
International Classification:
A61K 38/04
A01N 37/18
US Classification:
514 31
Abstract:
The presently disclosed subject matter relates to peptides having binding affinity for glycopeptide antibiotics and methods and compositions for delivering glycopeptide antibiotic to the surface of medical devices. The peptide compositions can comprise a peptide having binding affinity for a surface material of a medical device that is coupled to the peptide having binding affinity for glycopeptide antibiotic. Also provided are methods of applying the peptide compositions to a medical device by contacting the peptide compositions with a surface of the medical device. In addition, kits are provided comprising the peptide compositions.

Immune Response Modulator Alpha-2 Macroglobulin Complex

View page
US Patent:
20020127232, Sep 12, 2002
Filed:
Nov 20, 2001
Appl. No.:
09/989284
Inventors:
Salvatore Pizzo - Bahama NC, US
Hanne Gron - Chapel Hill NC, US
International Classification:
A61K039/395
C07K016/46
US Classification:
424/178100, 530/391100
Abstract:
Activation of -macroglobulin (M) with a nucleophilic compound followed by incubation of the activated M at elevated temperature with a biomolecule results in covalent incorporation of the intact biomolecule into the M molecule, without the use of proteinases. The thus-formed structurally defined and stable complex may be used as an antigen for stimulating the immune response, for example, in the form of a vaccine. Enhanced antigen presentation of a particular biomolecule is provided, especially for those that are poorly immunogenic; reduction of the immunodominance of particular epitopes is also provided.

Anti-Cd19 Antibodies And Uses In Oncology

View page
US Patent:
20060233791, Oct 19, 2006
Filed:
Feb 15, 2006
Appl. No.:
11/355905
Inventors:
Thomas Tedder - Durham NC, US
Yasuhito Hamaguchi - Kanazawa-City, JP
Hanne Gron - Durham NC, US
Norihito Yazawa - Tokyo, JP
International Classification:
A61K 39/395
US Classification:
424141100, 424144100
Abstract:
The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.

Anti-Cd19 Antibody Therapy For Autoimmune Disease

View page
US Patent:
20060263357, Nov 23, 2006
Filed:
May 5, 2006
Appl. No.:
11/429545
Inventors:
Thomas Tedder - Durham NC, US
Yasuhito Hamaguchi - Kanazawa City, JP
Hanne Gron - Durham NC, US
Norihito Yazawa - Tokyo, JP
International Classification:
A61K 39/395
US Classification:
424144100
Abstract:
The invention relates to immunotherapeutic compositions and methods for the treatment of autoimmune diseases and disorders in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.

Methods And Compositions For Promoting Localization Of Pharmaceutically Active Agents To Bone

View page
US Patent:
20080268015, Oct 30, 2008
Filed:
Apr 22, 2008
Appl. No.:
12/107098
Inventors:
Hanne Gron - Durham NC, US
David Duffin - Raleigh NC, US
International Classification:
A61F 2/00
A61K 47/00
A61K 38/00
C07K 7/00
A61K 35/12
A61P 19/00
C07K 14/00
C12N 15/11
C12N 15/00
US Classification:
424423, 514773, 514 12, 530326, 530327, 530328, 530329, 530325, 530324, 536 231, 4353201, 424 931
Abstract:
Compositions are provided comprising a family of peptides having binding specificity for bone, and their use to produce coating compositions. The coating compositions are used to deliver a pharmaceutically active agent to bone, and are used in methods related to bone implants, bone repair, and bone-related diseases.

Anti-Cd19 Antibodies And Uses In Oncology

View page
US Patent:
20090285808, Nov 19, 2009
Filed:
Mar 10, 2009
Appl. No.:
12/401310
Inventors:
Thomas F. Tedder - Durham NC, US
Yasuhito Hamaguchi - Kanazawa City, JP
Hanne Gron - Durham NC, US
Norihito Yazawa - Tokyo, JP
Assignee:
Duke University - Durham NC
International Classification:
A61K 39/395
US Classification:
4241331, 4241421, 4241781
Abstract:
The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.

Methods And Compositions For Delivery Of Glycopeptide Antibiotics To Medical Device Surfaces

View page
US Patent:
20100098737, Apr 22, 2010
Filed:
Oct 17, 2008
Appl. No.:
12/253750
Inventors:
Martyn Kerry Darby - Chapel Hill NC, US
Isaac Gilliam Sanford - Durham NC, US
Hanne Gron - Durham NC, US
Paul Theodore Hamilton - Cary NC, US
Shrikumar Ambujakshan Nair - Cary NC, US
Assignee:
Affinergy, Inc. - Research Triangle Park NC
International Classification:
A61F 2/00
A61K 38/16
A61L 33/12
C07H 21/04
C12N 15/64
A61P 31/04
US Classification:
424423, 514 12, 427 23, 536 231, 4353201
Abstract:
The presently disclosed subject matter relates to peptides having binding affinity for glycopeptide antibiotics and methods and compositions for delivering glycopeptide antibiotic to the surface of medical devices. The peptide compositions can comprise a peptide having binding affinity for a surface material of a medical device that is coupled to the peptide having binding affinity for glycopeptide antibiotic. Also provided are methods of applying the peptide compositions to a medical device by contacting the peptide compositions with a surface of the medical device. In addition, kits are provided comprising the peptide compositions.
Control profile
Hanne Gron from Larkspur, CA, age ~61 Get Report